^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    linclatamig (RG6286)

    i
    Other names: RG6286, BLYG8824A
    Associations

    News

    Trials
    Company:
    Roche
    Drug class:
    CD3 agonist, LY6G6D inhibitor
    Related drugs:
    Associations

    News

    Trials
    11ms
    A Study of BLYG8824A in Participants With Locally Advanced or Metastatic Colorectal Cancer (clinicaltrials.gov)
    P1, N=46, Completed, Genentech, Inc. | Active, not recruiting --> Completed | N=120 --> 46 | Trial completion date: Jan 2026 --> Dec 2024 | Trial primary completion date: Jan 2026 --> Dec 2024
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    |
    MSI (Microsatellite instability)
    |
    linclatamig (RG6286)
    over1year
    A Study of BLYG8824A in Participants With Locally Advanced or Metastatic Colorectal Cancer (clinicaltrials.gov)
    P1, N=120, Active, not recruiting, Genentech, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed • Metastases
    |
    MSI (Microsatellite instability)
    |
    linclatamig (RG6286)
    3years
    A Study of BLYG8824A in Participants With Locally Advanced or Metastatic Colorectal Cancer (clinicaltrials.gov)
    P1, N=120, Recruiting, Genentech, Inc. | N=60 --> 120
    Enrollment change • Metastases
    |
    MSI (Microsatellite instability)
    |
    linclatamig (RG6286)
    over5years
    A Study of BLYG8824A in Participants With Locally Advanced or Metastatic Colorectal Cancer (clinicaltrials.gov)
    P1; N=60; Recruiting; Sponsor: Genentech, Inc.
    New P1 trial • Clinical
    |
    MSI (Microsatellite instability)
    |
    linclatamig (RG6286)